In the current trading session, Adc Therapeutics SA’s (ADCT) stock is trading at the price of $2.60, a gain of 35.16% over last night’s close. So, the stock is trading at a price that is -57.04% less than its 52-week high of $6.04 and 175.77% better than its 52-week low of $0.94. Based on the past 30-day period, the stock price is -22.93% below the high and +37.44% above the low.
The 200-day Simple moving average is often placed more emphasis on by traders because of daily price changes. Investors will use the SMA-200 in different situations in trading activity as a key indicator to determine their support and resistance levels, and at the moment, ADCT’s SMA-200 is $3.4895.
It is also essential to consider ADCT stock ratios like the price-to-sales ratio, which is 3.55 for the last year.
How does Adc Therapeutics SA (ADCT) stock rate among analysts? Buy, sell, or hold?
The key to trading is to concentrate on the future rather than on the past. During uncertain times, it can be hard to make decisions. The analysts who understand how a market works are usually the most accurate at forecasting its future. Currently, there are 7 brokerage firms that recommend the stock as a Strong Buy. The ratings are commonly aggregated into a single number between 1 and 5. Buy or strong buy is scored 5, outperform is scored 4, hold is scored 3, underperform is scored 2 and strong sell is 1. Using a scale of 1-5, the current average recommendation is 4.57 in simple terms.
Adc Therapeutics SA (ADCT): Earnings History
Most analysts expect public companies to report earnings and revenue in line with their projections, but sometimes these figures vary from what they actually expected. In the current quarter, the company had earnings predictions made by 3 different analysts, who are expecting earnings to fall in between the range of -0.28 and -0.47 with an average Earnings Estimate of -0.38 which is in contrast with the last year earnings estimate of -1.03 and also replicates 63.11% growth rate year over year.
Adc Therapeutics SA (NYSE: ADCT) Ownership Details
I will give a breakdown of the key shareholders in Adc Therapeutics SA (ADCT). Recent figures show that the company’s insiders hold 21.03% of shares. A total of 106 institutional investors hold shares in the company, making 63.13% of its stock and 79.94% of its float.
Sep 30, 2024, it was reported that the Company’s largest institutional holder is Redmile Group, LLC holding total of 15.67 shares that make 16.21% of the company’s total number of shares and are currently priced at 43.1 million.
The securities firm Prosight Management, Lp holds 9.64 shares of ADCT, making it the second largest institutional shareholder. Taking this into account, the holding percentage comes to 9.97%, and the holding percentage of shares is valued at 26.51 million.
An overview of Adc Therapeutics SA’s technicals
In order to learn about trade movements and investor behavior, it is best to analyze the short, medium, and long term technical indicators along with the average volume of a stock. A 20-day average of the stock’s daily volume suggests Adc Therapeutics SA (ADCT) traded 477,069 shares per day, with a moving average of $2.3297 and price change of -0.4560. With the moving average of $2.7617 and a price change of -0.5260, about 396,462 shares changed hands on average over the past 50 days. Finally, ADCT’s 100-day average volume is 389,769 shares, alongside a moving average of $2.9140 and a price change of -1.3060.
